Cagrilintide
Also known as: Long-acting amylin analogue
A long-acting amylin analogue being investigated for appetite regulation, satiety, energy intake, and weight management.
COMPOUND CLASS
Investigational amylin receptor agonist peptide
PRIMARY PATHWAY
Amylin and calcitonin receptor signaling
PRIMARY AREAS OF RESEARCH
Satiety, appetite regulation, energy intake, weight physiology
RESEARCH STATUS
Investigational — phase 1/2 human trials published, phase 3 ongoing
EVIDENCE LEVEL
Early
OTHER NAMES
Long-acting amylin analogue
What Is Cagrilintide?
Cagrilintide is a long-acting compound designed to mimic amylin, a hormone the body makes naturally. Amylin is released alongside insulin after eating and takes part in the signaling system that governs hunger, fullness, and how much food is consumed.
The compound is engineered so that amylin-like activity lasts far longer than the natural hormone does. That extended duration is what makes it useful for studying appetite and energy balance over time.
Unlike compounds such as semaglutide, cagrilintide is not a GLP-1 receptor agonist. It works through the amylin signaling system, which gives researchers a separate biological pathway to investigate.
- What it is
- A long-acting lab-made version of amylin, a natural hormone released with insulin after eating.
- Category
- Metabolic and appetite-regulation research compound — amylin analogue.
- Main system involved
- The amylin signaling system linking the gut and pancreas to satiety centers in the brain.
- Research interest
- Hunger, fullness, food and calorie intake, body-weight regulation, and metabolic function.
- Research status
- Investigational. Studied on its own and alongside GLP-1-based compounds; phase 3 research is ongoing.
Why Are Researchers Interested?
A different pathway
Amylin signaling is distinct from GLP-1 signaling, so it offers researchers another route into appetite and energy-balance biology.
Hunger and satiety
Studies look at how sustained amylin signaling affects the sensation of hunger and the feeling of fullness after eating.
Energy intake and body weight
Controlled research measures changes in food and calorie intake and in body-weight regulation.
Combination research
Because amylin and GLP-1 pathways are different but complementary, researchers study them together — most prominently in the investigational combination CagriSema.
How It Works
Think of appetite regulation as a conversation between the digestive system and the brain. After food is consumed, hormones send signals that help the brain recognize nutrients have arrived and that the body is becoming full. Amylin is one of those signals.
Cagrilintide is designed to imitate amylin for a much longer period. Researchers are investigating whether strengthening this signaling pathway increases feelings of fullness, reduces hunger, and influences overall food intake.
Cagrilintide versus GLP-1 research: GLP-1-based compounds primarily target the GLP-1 receptor, while cagrilintide targets the amylin signaling system. Because those pathways are different but complementary, researchers have become especially interested in studying them side by side.
Current Areas of Research
Appetite regulation
Research into how amylin signaling influences hunger and the desire to eat.
Satiety
Research into how cagrilintide may affect feelings of fullness after eating.
Energy intake
Studies examining changes in overall food and calorie consumption.
Body-weight regulation
Clinical research investigating the relationship between long-acting amylin signaling and changes in body weight.
Metabolic research
Research examining the broader relationship between amylin signaling and metabolic regulation.
Combination research
Research investigating cagrilintide alongside GLP-1 receptor agonists, particularly semaglutide.
What Does the Evidence Actually Say?
Early — published randomized human trials exist, including combination studies, but the compound is not approved and long-term outcome data is not yet available.
Side Effects & Safety Research
Documented in research
- Published trials report gastrointestinal effects such as nausea as the most common finding.
Possible or theoretical
- Injection-site reactions have been described in trial reporting.
Where evidence is insufficient
- Long-term safety is unknown; the compound remains investigational.
What We Don't Know Yet
- Cagrilintide remains under clinical investigation, and long-term outcomes are not yet established.
- Optimal applications, dose levels, safety, and tolerability continue to be studied.
- How effects differ across populations, and between standalone and combination use, is still being characterized.
- How amylin-pathway effects compare with other metabolic pathways and compounds remains an open research question.
- Results reported in controlled clinical trials describe group averages and do not guarantee that any individual would experience the same result.
Frequently Asked Questions
Research References
- Lau DCW et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. The Lancet, 2021.
- Enebo LB et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management. The Lancet, 2021.
- Hay DL, Chen S, Lutz TA, Parkes DG, Roth JD. Amylin: pharmacology, physiology, and clinical potential. Pharmacological Reviews, 2015.
Key Takeaway
Cagrilintide is a long-acting amylin analogue being investigated as a different approach to appetite and metabolic research. Rather than acting through the GLP-1 receptor, it targets the amylin signaling system involved in hunger, satiety, and energy intake. Current clinical research is advanced: phase 3 work has studied it as a standalone compound, with one phase 3 analysis reporting an average body-weight reduction of roughly 11.8% after 68 weeks among participants assigned cagrilintide 2.4 mg under the trial's efficacy estimand, compared with about 2.3% for placebo — group averages that do not guarantee any individual result. It has also entered a dedicated phase 3 program known as RENEW, and is being studied with semaglutide in the investigational combination CagriSema, which is not an approved treatment. Cagrilintide remains investigational, and research is ongoing.
Related Research
This information is provided for educational purposes only and summarizes current areas of scientific research. It is not medical advice, a treatment recommendation, or an instruction for personal use. Research findings may be preliminary, limited, or subject to change as new evidence becomes available.